Puerto Rico Was Once A Pharmaceutical Powerhouse—It Can Become One Again

Key Concepts:

• Pharmaceutical manufacturing in Puerto Rico
• Section 936 of the US tax code
• Reshoring pharmaceutical production
• Economic incentives vs. mandates/tariffs
• US economic security and supply chain resilience
• Pro-growth tax policy

1. Puerto Rico's Pharmaceutical History and Decline:

• Puerto Rico was once a "premier pharmaceutical manufacturing hub" due to skilled labor, US legal protections, and Section 936 of the US tax code.
• Section 936 allowed American corporations operating in Puerto Rico to avoid federal taxes on profits earned on the island.
• This attracted major companies, fueling jobs, innovation, and prosperity.
• At its peak, Puerto Rico produced a "significant share of America's most essential medicines."
• The phasing out of Section 936 led to factory closures, job losses, and economic decline in Puerto Rico.
• The US became "dangerously dependent on overseas supply chains," many centered in China.

2. The Argument for Restoring Incentives:

• Congress should restore incentives to make Puerto Rico a pharmaceutical powerhouse again.
• This would boost US economic security, create high-paying jobs, and help rebuild Puerto Rico's economy.
• The approach should be based on "smart progrowth tax policy" to unleash private investment, using "carrots, not sticks."
• Current US policy relies on tariffs, mandates, and heavy-handed regulation, which "rarely works."
• Companies flee high costs and uncertainty, but respond positively to lower barriers and entrepreneurial freedom.

3. Puerto Rico's Advantages:

• Puerto Rico offers a "bilingual educated workforce," "proximity to US markets," and the "stability of operating under US laws."
• Restoring tax incentives would make it attractive for pharmaceutical companies to build and expand plants there.
• New factories would create "hundreds of high-skilled jobs," supporting many more in services, logistics, and construction.
• The "ripple effect would be transformational."

4. Strengthening US Strategic Resilience:

• Revitalizing Puerto Rico's pharmaceutical sector would strengthen America's strategic resilience.
• The pandemic exposed the "dangerous dependence on foreign suppliers for critical drugs and medical supplies."
• Incentivizing Puerto Rico is the "fastest, most cost-effective way to bring manufacturing back within US borders."
• This ensures quality, safeguards supply chains, and reduces vulnerability to geopolitical shocks.

5. Economic Benefits for Puerto Rico:

• A revived pharmaceutical base would spur investment in infrastructure, including "reliable power" and "modern ports."
• It would expand the island's tax base, enabling better schools, health care, and public services.
• It would also stem the out-migration of young Puerto Ricans by offering them "real opportunities at home."

6. Addressing Criticisms:

• The argument that this is "just corporate welfare" is refuted.
• "Progrowth tax policy is not about picking winners and losers. It's about creating conditions where everyone wins."
• When companies invest, workers earn more, local communities thrive, and government revenues rise.
• The alternative, punishing companies with tariffs or relying on foreign imports, is "far more costly in the long run."

7. Conclusion:

• Puerto Rico can once again be a global leader in pharmaceutical manufacturing.
• Washington should act quickly, understanding that "carrots work, sticks don't."
• The goal is to bring back the policies that made Puerto Rico a "shining success story" for the island, for America's patients, and for the nation's economic security.

Notable Quotes:

• "Puerto Rico was once a pharmaceutical powerhouse. It can become one again." - Steve Forbes
• "Carrots work, sticks don't." - Steve Forbes
• "Progrowth tax policy is not about picking winners and losers. It's about creating conditions where everyone wins." - Steve Forbes

Technical Terms and Concepts:

• Section 936: A provision of the US tax code that allowed American corporations operating in Puerto Rico to avoid federal taxes on profits earned on the island.
• Reshoring: The process of bringing manufacturing and production back to a company's home country.
• Pro-growth tax policy: Tax policies designed to stimulate economic growth by encouraging investment and entrepreneurship.
• Supply chain resilience: The ability of a supply chain to withstand disruptions and maintain operations.

Logical Connections:

The video presents a clear argument: Puerto Rico's past success in pharmaceutical manufacturing was due to specific tax incentives (Section 936). Removing these incentives led to economic decline and increased US dependence on foreign supply chains. Therefore, restoring similar incentives is the logical solution to revitalize Puerto Rico's economy and strengthen US economic security. The argument is supported by highlighting Puerto Rico's existing advantages and refuting potential criticisms.

Synthesis/Conclusion:

The main takeaway is that restoring targeted tax incentives for pharmaceutical companies in Puerto Rico is a strategic move that would benefit both the island's economy and the United States' economic security. This approach, based on incentivizing private investment rather than relying on mandates or tariffs, is presented as a more effective and sustainable solution for reshoring critical industries and fostering economic growth.